UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 or 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of: September 2025
Commission File Number: 001-40207
Waldencast plc
(Translation of Registrant’s name into English)
81 Fulham Road
London, SW3 6RD
United Kingdom
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Press Release
On September 10, 2025, Waldencast plc (the “Company”) issued an announcement titled “Waldencast Announces FDA Approval of
Obagi® saypha® MagIQ™ Injectable Hyaluronic Acid Gel Under the Obagi Medical Brand”, a copy of which is attached as Exhibit 99.1 to this Form 6-K.
The information in this report on Form 6-K (including Exhibit 99.1 hereto) (“Report”) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as
expressly set forth by specific reference in such a filing.
EXHIBIT INDEX
|
EXHIBIT NO.
|
|
DESCRIPTION
|
|
99.1
|
|
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, Waldencast plc has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
| |
|
Waldencast plc
|
| |
|
(Registrant)
|
| |
|
|
|
|
Date: September 10, 2025
|
By:
|
/s/ Manuel Manfredi
|
| |
|
Name:
|
Manuel Manfredi
|
| |
|
Title:
|
Chief Financial Officer and Principal Financial Officer
|